Establishing a Consensus Algorithm for H. Pylori Screening, Diagnosis, Initial Management, and Referral Protocols for Primary Care Physicians.

Main Article Content

Sarah Abere
Ozuomba Sixtus
Ngozi Koko-James

Keywords

Consensus, Algorithm, H. Pylori, Clinical Guide , Primary Care.

Abstract

Background: Helicobacter pylori (H. pylori) infection is a significant public health concern, contributing to various gastrointestinal disorders, including peptic ulcers and gastric cancer. The infection is highly prevalent in Africa, but still diagnostic and treatment challenges persist in primary care settings. Effective treatment regimens are therefore crucial for eradicating this infection and preventing complications.  This study aimed to develop a consensus-based algorithm for H. pylori management optimized for Primary care settings utilizing data from primary care physicians, patient screening, and treatments.


Methodology: A cross-sectional study was conducted among forty-four primary care physicians involved in diagnosing and treating H. pylori infection. They were provided with a data Collection Form (DCF) and an H. pylori rapid antibody test kit. All the questionnaire responses and the result of rapid antibody test were recorded and analyzed. A panel of experts involving senior family medicine doctors, and a gastroenterologist via a modified Delphi process of discussions on the DCF responses, and test results from the 44 physicians arrived at a consensus-based treatment algorithm developed to guide clinical decision-making for H. pylori management.


Results: This study comprised 245 patients with a female preponderance and mean age of 35.0±11.5 years. The most common symptoms from the DCF were epigastric pain, nausea/vomiting and bloating in 74.5%, 52.7% and 35% respectively while the mean duration of symptoms was 3weeks. Constipation and irritability were the least common symptoms with heartburn reported less frequently in the H. Pylori positive cases. 79.9% of the 245 patients were H. Pylori treatment naïve with a higher likelihood (57.1%) of having a positive antibody test. It was recommended that both treatment experienced and naïve patients with epigastric or abdominal pain, nausea vomiting and/or bloating with symptom duration > 2weeks be tested and eradicated while those with alarm symptoms be referred to the specialist.


Conclusion: The proposed algorithm provides a comprehensive guide for Physicians at the primary and secondary care level in selecting the most effective treatment regimen for H. pylori infection. H. Pylori antibody testing is a primary screening tool for patients with persistent symptoms or those lasting greater than 2weeks and where positive confirmatory test is recommended.

Abstract 183 | PDF Downloads 122 EPUB Downloads 64

References

1. Marshall, B. J., & Warren, J. R. (1984). Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. The Lancet, 323(8390), 1311-1315.

2. Kusters, J. G., van Vliet, A. H., & Kuipers, E. J. Pathogenesis of Helicobacter pylori infection. Clinical Microbiology Reviews 2006;19(3), 449-490.

3. Smith S I, Ajayi A, Jolaiya T F, Essiet U. Prevalence, diagnosis and treatment of Helicobacter pylori infection in Nigeria. Nigerian Journal of gastroenterology and hepatology. 2022; 14(1):2-10.

4. Nwankwo, I.U, Edward, K.C, Nwoba, C.N, Ezeanwe, G.O. Prevalence of Helicobacter pylori among Suspected Stomach Ulcer Patients Attending two Mission Hospitals in Umuahia, Abia State, Nigeria. Nigerian Journal of Microbiology. 2021; 35(2): - 5927 – 5935.

5. Bello, A.K., Umar, A.B. and Borodo, M.M. (2018). Prevalence and risk factors for H. Pylori infection in Gastroduodenal diseases in Kano, Nigeria. African Journal of Medical and Health Sciences. 2018;17: 41-46.

6. Ayodele MB, Aaron UU, Oluwatayo GA, Wariso KT. Prevalence of Helicobacter pylori Infection in Port Harcourt Using Antibody Diagnostic Technique. Int. J. Innovative Healthcare Res. 2018; 6 (1):24-28.

7. Fekadu, S., Engiso, H., Seyfe, S. et al. Effectiveness of eradication therapy for Helicobacter pylori infection in Africa: a systematic review and meta-analysis. BMC Gastroenterol. 2023;(55): 1-11.

8. Huang TT, Cao YX, Cao L. Novel therapeutic regimens against Helicobacter pylori: an updated systematic review. Front Microbiol. 2024; 7(15):1418129.

9. Kim SY, Choi DJ, Chung JW. Antibiotic treatment for Helicobacter pylori: Is the end coming? World J Gastrointest Pharmacol Ther. 2015;6(4):183-98.

10. Smith SI, Schulz C, Ugiagbe R, et al. Helicobacter pylori Diagnosis and Treatment in Africa: The First Lagos Consensus Statement of the African Helicobacter and Microbiota Study Group. Dig Dis. 2024;42(3):240-256.

11. Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353–67.

12. Smith SI, Ajayi A, Jolaiya T, Onyekwere C, Setshedi M, Schulz C, et al. Helicobacter pylori infection in Africa: update of the current situation and challenges. Dig Dis. 2022;40(4):535–44.

13. Chukwudike ES, Moss SF, Asombang AW. Management of Helicobacter Pylori infection in Africa: The current challenges and peculiarities. Available at https://www.worldgastroenterology.org/publications/e-wgn/e-wgn-expert-point-of-view-articles-collection/management-of-helicobacter-pylori-infection-in-africa-the-challenges-and-peculiarities accessed 5 October 2025.

14. Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou JM, Schulz C, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022;71(9):1724–62.

15. European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6-30.

16. Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. Gastroenterology. 2018;155(5):1372-1382.e17.

17. World Gastroenterology Organisation. Global Guidelines: Helicobacter pylori (English). WGO; 2021. Available from: https://www.worldgastroenterology.org/UserFiles/file/guidelines/helicobacter-pylori-english-2021. Accessed 5 October 2025.

18. Bomme M, Hansen JM, Wildner-Christensen M, Hallas J, Schaffalitzky de Muckadell OB. Effects of Community Screening for Helicobacter pylori: 13-Year Follow-Up Evaluation of a Randomized Controlled Trial. Clin Gastroenterol Hepatol. 2017; 15:1715–1723.e7.

19. Wang YK, Kuo FC, Liu CJ, et al. Diagnosis of Helicobacter pylori infection: Current options and developments. World J Gastroenterol. 2015;21(40):11221–11235.

20. Cardos AI, Maghiar A, Zaha DC, Pop O, Fritea L, Miere Groza F, Cavalu S. Evolution of Diagnostic Methods for Helicobacter pylori Infections: From Traditional Tests to High Technology, Advanced Sensitivity and Discrimination Tools. Diagnostics (Basel). 2022;12(2):508.

21. Yuan Y, Ford AC, Khan KJ, et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2013;12:CD008337.

22. Cho JH, Jin SY. Current guidelines for Helicobacter pylori treatment in East Asia 2022: Differences among China, Japan, and South Korea. World J Clin Cases. 2022 Jul 6;10(19):6349-6359.

23. Moayyedi P, Lacy BE, Andrews CN, et al.; American College of Gastroenterology (ACG) and Canadian Association of Gastroenterology (CAG). AGA/ACG Clinical Guideline: Management of Dyspepsia. Am J Gastroenterol. 2017;112(7):988–1003.

24. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017 Feb;112(2):212-239.

25. Reconciliation of Recent Helicobacter pylori Treatment Guidelines in a Time of Increasing Resistance to Antibiotics. Gastroenterology. 2019 Jul;157(1):44-53.